Key Long-Term Studies on Lyrica (Pregabalin)
Pfizer-sponsored open-label studies tracked Lyrica for up to 2 years in patients with diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. These found sustained pain relief but noted common issues like dizziness (up to 30% of patients), somnolence (20-25%), and weight gain (averaging 7% body weight increase). Serious adverse events, including peripheral edema and blurred vision, led to discontinuation in 10-15% of participants.[1]
A 2017 Danish registry study followed over 11,000 epilepsy patients on pregabalin for a median of 1.5 years (some up to 5+ years). It linked long-term use to higher risks of falls (HR 1.6), fractures (HR 1.4), and motor vehicle accidents (HR 1.8), especially at higher doses.[2]
What Risks Show Up After 1+ Years?
Observational data from the UK’s Clinical Practice Research Datalink (over 50,000 pregabalin users, mean follow-up 2.5 years) reported increased chances of heart failure (OR 1.3), pneumonia (OR 1.5), and acute kidney injury (OR 1.2) compared to non-users. Dose-dependent effects were clear: risks doubled above 300 mg/day. These tied to pregabalin's GABA-mimetic action, which can impair coordination and respiration over time.[3]
Cancer concerns arise from animal studies (rats showed dose-related tumors after 2 years), but human data from post-marketing surveillance (millions of patient-years) shows no clear signal. The FDA label notes this as a precaution without confirmed risk.[4]
How Does Tolerance or Dependence Develop Long-Term?
Multiple cohort studies (e.g., a 2020 review in Pain Medicine of 20+ trials) show tolerance to pain relief in 20-40% of chronic users after 6-12 months, prompting dose escalation. Withdrawal symptoms—affecting 40-60% upon abrupt stop—include anxiety, insomnia, sweating, and seizures, resembling benzodiazepine dependence. A 1-year fibromyalgia trial saw 15% develop these after tapering.[5]
Patient Outcomes and Real-World Data
A 2022 meta-analysis in The Lancet Neurology (38 studies, >20,000 patients, up to 3 years) confirmed efficacy wanes slightly after year 1 for neuropathic pain, with 25% dropout from side effects. Quality-of-life scores improved initially but plateaued, offset by cognitive fog reports (memory issues in 10-15%). Elderly patients (>65) faced 2x higher adverse event rates.[6]
Regulatory Warnings and Guidelines
FDA black-box warning (2019 update) highlights respiratory depression risk in long-term combo use with opioids or in COPD patients. EMA guidelines cap treatment duration at 12 weeks for anxiety unless benefits outweigh risks. NICE (UK) advises regular review after 6 months, with deprescribing trials.[7]
No DrugPatentWatch data applies here, as Lyrica's key patents expired in 2018-2019, shifting focus to generics.
[1] Pfizer Lyrica prescribing information (2023 update), fda.gov
[2] Gaist et al., Neurology (2017), doi:10.1212/WNL.0000000000004027
[3] Hung et al., BMJ (2020), doi:10.1136/bmj.m2036
[4] FDA Adverse Event Reporting System (FAERS) summary (2023), fda.gov
[5] Cooper et al., Pain Medicine (2020), doi:10.1093/pm/pnz324
[6] Derry et al., Lancet Neurology (2022), doi:10.1016/S1474-4422(21)00458-3
[7] EMA pregabalin assessment report (2019), ema.europa.eu